Spero Therapeutics
SPRO
48 hedge funds and large institutions have $18M invested in Spero Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 11 closing their positions.
1,300% more call options, than puts
Call options by funds: $14K | Put options by funds: $1K
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0.17% more ownership
Funds ownership: 25.54% → 25.7% (+0.17%)
11% less funds holding
Funds holding: 54 → 48 (-6)
24% less capital invested
Capital invested by funds: $23.7M → $18M (-$5.63M)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$471K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$466K |
| 3 |
Renaissance Technologies
New York
|
+$183K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$177K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
-$425K |
| 2 |
Man Group
London,
United Kingdom
|
-$212K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$140K |
| 4 |
Squarepoint
New York
|
-$137K |
| 5 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$109K |
SPRO Hedge Fund Activity: Q2 2024 in Review
48 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2024, worth a combined $18M — down 24% from $23.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SPRO and 5 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $471K. The largest seller was Shay Capital, cutting an estimated $425K.
- 48 institutional investors held Spero Therapeutics (SPRO) as of Q2 2024, down from 54 in Q1 2024.
- Funds reported $18M of Spero Therapeutics stock for Q2 2024, down 24% quarter-over-quarter.
- 5 funds opened new Spero Therapeutics positions in Q2 2024 and 11 closed out, a net change of -6 holders.
- The largest Spero Therapeutics buyer in Q2 2024 was Citadel Advisors, an estimated $471K added.
- The largest Spero Therapeutics seller in Q2 2024 was Shay Capital, an estimated $425K sold.
Based on aggregated 13F filings for Q2 2024.